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Abstract
Pulses of insulin from pancreatic beta-cells help maintain blood glucose in a narrow range, although the source of these
pulses is unclear. It has been proposed that a positive feedback circuit exists within the glycolytic pathway, the autocatalytic
activation of phosphofructokinase-1 (PFK1), which endows pancreatic beta-cells with the ability to generate oscillations in
metabolism. Flux through PFK1 is controlled by the bifunctional enzyme PFK2/FBPase2 (6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase) in two ways: via (1) production/degradation of fructose-2,6-bisphosphate (Fru2,6-BP), a potent
allosteric activator of PFK1, as well as (2) direct activation of glucokinase due to a protein-protein interaction. In this study,
we used a combination of live-cell imaging and mathematical modeling to examine the effects of inducibly-expressed PFK2/
FBPase2 mutants on glucose-induced Ca
2+ pulsatility in mouse islets. Irrespective of the ability to bind glucokinase, mutants
of PFK2/FBPase2 that increased the kinase:phosphatase ratio reduced the period and amplitude of Ca
2+ oscillations.
Mutants which reduced the kinase:phosphatase ratio had the opposite effect. These results indicate that the main effect of
the bifunctional enzyme on islet pulsatility is due to Fru2,6-BP alteration of the threshold for autocatalytic activation of PFK1
by Fru1,6-BP. Using computational models based on PFK1-generated islet oscillations, we then illustrated how moderate
elevation of Fru-2,6-BP can increase the frequency of glycolytic oscillations while reducing their amplitude, with sufficiently
high activation resulting in termination of slow oscillations. The concordance we observed between PFK2/FBPase2-induced
modulation of islet oscillations and the models of PFK1-driven oscillations furthermore suggests that metabolic oscillations,
like those found in yeast and skeletal muscle, are shaped early in glycolysis.
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Introduction
The plasma insulin pulses arising from pancreatic beta-cells [1]
are strongest in the portal blood system, more effective than
continuous administration in suppressing hepatic glucose output
[2,3], and lost in diabetics and their near relatives [4,5]. Befitting
their role as metabolic sensors for the organism, beta-cells adjust
their metabolic output in accordance with plasma glucose
concentration, and not just their own energy requirements.
Glucose sensing is mediated by glucokinase, which is rate-limiting
and controls metabolic flux into phosphofructokinase-1 (PFK1)
[6]. As the archetypal metabolic pathway, the initial steps of
glycolysis have been biochemically characterized and computa-
tionally modeled, leading to the proposal that PFK1 activity
determines the oscillatory activity of beta-cells [7,8] and governs
the downstream oscillations observed in metabolism (mitochon-
drial NADH and O2, ATP [9–11], electrical activity (KATP and
Ca
2+ channel activity) [12], and finally, pulsatile insulin release.
The bifunctional enzyme PFK2/FBPase2 (phosphofructo-2-
kinase/fructose-2,6-bisphosphatase) is uniquely positioned to alter
flux through PFK1 in two complementary ways. First, PFK2/
FBPase2 is the sole catalyst for the production and degradation of
fructose 2,6-bisphosphate (Fru2,6-BP), which allosterically acti-
vates PFK1 even more potently than its own product, fructose 1,6-
bisphosphate (Fru1,6-BP), overriding the feedback inhibition of
PFK1 by ATP and citrate [13–16]. Second, PFK2/FBPase2 has
been proposed to bind and directly activate glucokinase (GK) [17–
20], which controls the flux of fructose 6-phosphate (Fru-6P)
substrate into PFK1 [6]. In support of this latter pathway, insulin-
secreting cells overexpressing GK and PFK2/FBPase2 showed
enhanced glucokinase activity, glycolytic flux, and glucose-
stimulated insulin secretion [21,22], while downregulation of
PFK2/FBPase2 using siRNAs in INS-1E cells decreased glucoki-
nase activity and insulin secretion [23]. While providing a
biochemical framework, these studies have not addressed pulsa-
tility.
The goal of this study was to determine the effects of the positive
feedback provided by PFK2/FBPase2 and its product Fru2,6-BP
on islet oscillations. Do they amplify or attenuate oscillations?
What effect do they have on the oscillation frequency? Which of
the two feedback pathways dominates? Using data obtained from
time-lapse imaging of islet Ca
2+ oscillations under conditions of
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34036altered PFK2/FBPase2 activity, we show that PFK2/FBPase2
modulates the frequency of islet oscillations, primarily through the
effect of its product Fru2,6-BP on PFK1. These data can be
understood in terms of the influence of Fru2,6-BP on endogenous
glycolytic oscillations, as we demonstrate with a computational
model.
Results
Islet Ca
2+ oscillations are shaped by mutants of PFK2/
FBPase2
To test the effects of PFK2/FBPase2 on islet oscillations we
carried out a series of experiments in mouse pancreatic islets
expressing adenovirally-delivered mutants of the islet isoform of
PFK2/FBPase2, a pfkfb2 gene product [23,24]. Each of the four
PFK2/FBPase2 mutants used in this study (Fig. 1A) was N-
terminally tagged with a Degradation Domain (DD), which
permits transcription and translation but prevents the accumula-
tion of functional protein in the cytosol due to rapid proteosomal
degradation; degradation is inhibited in a controlled way by the
addition of a small cell-permeant molecule, Shield1 [25]. This
inducible expression system allowed direct comparison between
virally-transduced islets from the same isolation treated with either
1 mM Shield1 or vehicle (0.1% DMSO), neither of which had
effects when applied alone.
Our first two manipulations focused on the alteration of Fru2,6-
BP levels using truncation mutants of PFK2/FBPase2 in which
either the C-terminal phosphatase or the N-terminal kinase
domain was selectively deleted (DD-PFK2 and DD-FBPase2,
respectively) [26–30]. As a complementary approach, we con-
structed DD-tagged phosphatase-dead (H259A) and kinase-dead
(T55V) mutants of PFK2/FBPase2; these point mutants target the
active site of each domain while leaving the opposing reaction site
catalytically active [31–33]. Thus, the DD-H259A mutant
increases [34] and the DD-T55V decreases [35] the kinase/
bisphosphatase ratio. In addition to altering Fru2,6-BP levels, the
H259A and T55V mutants have been implicated in the direct
binding and activation of GK [17,19–21]. However, because full-
length PFK2/FBPase2 is required for the interaction with GK (see
the co-immunoprecipitation and FRET experiments in Figure S1),
a comparison between the point mutants and truncation mutants
provides a method for discerning possible effects of PFK2/
FBPase2 on PFK1 from effects on GK.
From the Western blots shown in Figures 1B and 1C it can be
seen that the DD-tagged constructs were largely degraded in the
absence of Shield1, whereas the presence of 1 mM Shield1 was
permissive for an increase in protein levels. We found the kinetics
of the increase in DD-tagged proteins upon Shield1 treatment to
be slow. Based on imaging of Min6 cells expressing DD-
mCerulean (not shown), increases in expression with Shield1 were
not observable in , 1 hr unless undesirably high viral titers were
used. In islets, 3D confocal imaging of the PFK2/FBPase2
mutants expressing an IRES2-linked mCherry indicated penetra-
tion of the adenovirus up to 17 mm (see the video file in Movie S1
online), about two cell layers deep. This would be expected to
cover ,70% of a 100 mm islet, but this is likely an overestimate
due to incomplete transduction. Thus, the success of the
experiments relies on intra-islet synchronization due to (1) gap
junction-mediated electrical coupling between a beta-cell and its
5–6 adjacent neighbors [36], as well as (2) bidirectional coupling
between membrane Ca
2+ flux and metabolism [37,38].
Time-lapse imaging was used to compare the Ca
2+ oscillations
induced by 11.1 mM glucose in islets that had been transduced
with either DD-PFK2 or DD-FBPase2. While transduction or
vehicle alone did not affect the islet oscillations (not shown), from
the representative recordings of Shield1-treated islets shown in
Figure 2A, it can be seen that islets expressing DD-PFK2 exhibited
Ca
2+ oscillations that were faster and reduced in amplitude
compared to those expressing DD-FBPase2. Furthermore we
observed a synchronous response from the entire islet, indicating
crosstalk between the transduced and untransduced cells.
Compared with vehicle treatment, the application of Shield1
dramatically reduced the mean oscillatory period and amplitude of
islet Ca
2+ oscillations by 27% and 35%, respectively, in DD-PFK2
expressing islets (Figs. 2B, C). In contrast, the average period and
amplitude of DD-FBPase2 transduced islets were increased by
41% and 30%, respectively, upon Shield1 treatment, and
exhibited a ,2-fold increased period and ,3-fold increased
amplitude relative to oscillations in DD-PFK2 expressing islets
(Figs. 2B, 2C). Taken together, these experiments indicate that the
oscillatory behavior of islets is modulated by Fru2,6-BP levels.
We then compared the Ca
2+ oscillations induced by 11.1 mM
glucose in islets that had been transduced with either DD-H259A
or DD-T55V. As exemplified by the traces shown in Fig. 3A,
Shield1-treated islets expressing phosphatase-dead DD-H259A
exhibited [Ca
2+]i oscillations that were significantly faster (by 44%,
on average) than those expressing kinase-dead DD-T55V.
Compared with control, Shield1 treatment induced a 26%
Figure 1. Inducible expression of degradation-domain (DD)-
tagged mutants of PFK2/FBPase2 in pancreatic islets. (A)
Schematic of DD-tagged mutants of PFK2/FBPase2. (B and C) Western
blots of islets transduced with DD-PFK2 and DD-FBPase2 truncations
mutants (B), or DD-tagged phosphatase-dead PFK2/FBPase2 (DD-
H259A) and kinase-dead PFK2/FBPase2 (DD-T55V) point mutants (C),
treated with either vehicle (0.1% DMSO) or 1 mM Shield1, and visualized
with an anti-DD antibody. Representative of three independent
experiments (50 islets per treatment).
doi:10.1371/journal.pone.0034036.g001
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2+ oscillations of DD-
H259A transduced islets, whereas the DD-T55V transduced islets
exhibited a comparable increase in period following Shield1
treatment (18%) (Fig. 3B). The amplitude of the oscillations was
not affected in either case (Fig. 3C). It is notable that even in the
absence of Shield1 the initial periods of the oscillations vary (cf.,
Figs. 2B and 3B). This variability is expected and most likely due to
‘islet imprinting’. That is, the average period of slow oscillations
tends to be consistent between islets from the same mouse while
varying considerably (from less than 1 min to about 7 min)
between mice [39,40]. Consequently, as the controls for Figs. 2
and 3 were done on different days with different mice, one would
expect significant variation in frequencies. Nonetheless, the GK-
interacting mutants (H259A and T55V), which increase and
decrease Fru2,6-BP levels, respectively, had opposite effects on
oscillation period whereas they would have been predicted to have
the same effect on GK, indicating that the predominant effect of
PFK2/FBPase2 on islet oscillatory behavior appears to occur
through its actions on PFK1, rather than GK.
Fructose-2,6-bisphosphate can speed up or terminate
glycolytic oscillations: model simulations
We have shown that expression of PFK2/FBPase2 mutants
known to elevate the levels of Fru2,6-BP above physiologic
concentrations resulted in higher-frequency oscillations, while
reducing Fru2,6-BP had the opposite effect. In this section, we use
a mathematical model of PFK1-mediated glycolytic oscillations
[41] to illustrate how this might occur, and further, we show that
levels of Fru2,6-BP that are insufficient to terminate the
oscillations outright may be able to increase their frequency while
decreasing their amplitude, akin to the experimental results shown
in Figs. 2 and 3. We then examine the consequences of a simulated
increase in Fru2,6-BP on a more complete model of the pancreatic
b-cell.
The model we used to simulate beta-cell glycolytic oscillations
was the same used in our previous studies [37,38]. It consists of
differential equations for the concentrations of the PFK1 substrate
Fru6-P and the product Fru1,6-BP:
dFru6{P
dt
~m1m2 JGK{JPFK1 ðÞ ð 3Þ
dFru1,6{BP
dt
~m1 JPFK1{0:5JGPDH ðÞ ð 4Þ
where m1 is a scaling factor that adjusts oscillation frequency in this
stand-alone glycolytic model for the removal of the calcium
feedback that exists in the full Dual Oscillator Model (DOM) used
in the next section (see Methods; we use m1~2 to produce ,7 min
oscillations in the absence of Fru2,6-BP) and m1~
1
3
relates Fru6-P
and glucose 6-phosphate concentrations. The enzymatic fluxes are
Figure 2. Effect of expressing PFK2/FBPase2 truncation
mutants on islet Ca
2+ oscillations. (A) Representative recordings
of islet Ca
2+ in the presence of the indicated constructs and 1 mM
Shield1; note the difference in scaling. (B and C) Average oscillatory
period (B) and amplitude (C) as determined from .20 min of
intracellular Ca
2+ measurements of transduced islets treated with
vehicle or Shield1. Numbers in parentheses indicate the number of
islets measured in $4 independent experiments. 11.1 mM glucose was
used in all experiments. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0034036.g002
Figure 3. Effect of expressing PFK2/FBPase2 point mutants on
islet Ca
2+ oscillations. (A) Representative recordings of islets Ca
2+ in
the presence of the indicated constructs and 1 mM Shield1. (B and C)
Average oscillatory period (B) and amplitude (C) were determined from
.20 min of intracellular Ca
2+ measurements of transduced islets
treated with vehicle or Shield1. Numbers in parentheses indicate the
number of islets measured in $4 independent experiments. 11.1 mM
glucose was used in all experiments. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0034036.g003
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glyceraldehyde 3-phosphate dehydrogenase, and JPFK1 for PFK1,
which converts Fru6-P to Fru1,6-BP. The latter reaction is
allosterically stimulated by Fru1,6-BP and inhibited by ATP
(which we hold constant at 800 mM in Fig. 4A). It is the positive
feedback on PFK1 provided by Fru1,6-BP, combined with a
slower reduction in the substrate Fru6-P, that endows the system
with the ability to oscillate.
Figure 4A (blue) shows the oscillation in Fru1,6-BP produced by
the model when JGK~200 mMm s
-1 and [Fru2,6-BP]=0. The
basis for the oscillation can be understood in terms of the nullclines
of the two variables. These are the curves shown in the Fru6-P/
Fru1,6-BP phase plane (Fig. 4B) where the derivatives of the
variables are zero. The Fru6-P nullcline
dFru6{P
dt
~0

is the
black curve, which shows that Fru6-P declines when Fru1,6-BP
rises because the former is converted into the latter. The Fru1,6-
BP nullcline
dFru1,6{BP
dt
~0

is the solid blue curve, which is
S-shaped, reflecting the strong nonlinear effect of Fru1,6-BP on
PFK1. Focusing on the bottom leg of the S, we see that the steady
state response of Fru1,6-BP to a rise in Fru6-P is negligible until
Fru6-P crosses the threshold represented by the sharp lower knee
of the S, which results in a rapid rise in Fru1,6-BP as it is produced
by PFK1 and a fall in Fru6-P as it is consumed. This threshold
crossing is responsible for the surge of Fru1,6-BP in the blue
portion of the time course in Fig. 4A. The Fru1,6-BP nullcline
finally turns subtly back to the right, creating an upper knee as
very high Fru6-P drives a maintained increase in Fru1,6-P.
These curves divide up the Fru6-P/Fru1,6-BP plane into sectors
in which the derivatives have a fixed sign and general direction of
flow. Equilibrium occurs at the intersection of the nullclines where
both derivatives are 0, and depending on its location, the
equilibrium may be stable or unstable. When the equilibrium is
on the middle branch of the S-shaped curve, the equilibrium may
be unstable (intersections on the lower or upper branches produce
stable equilibria). In fact, this is the case, and the instability of the
equilibrium gives rise to a stable oscillatory solution (indicated by
the blue dashed line in Fig. 4B).
Fructose-2,6-bisphosphate enters the PFK1 reaction much as
Fru1,6-BP does, but it binds with a higher affinity (the rate JPFK1 is
increased by Fru2,6-BP, which competes with Fru1,6-BP; see
Methods for model implementation). When Fru2,6-BP is increased
from 0 to 0.1 mM the glycolytic oscillation amplitude is greatly
reduced while its frequency is increased (Fig. 4A, green). This is
due largely to a change in the shape of the Fru1,6-BP nullcline
(Fig. 4B, green solid curve); the lower knee of the curve is shifted
leftward, so that the horizontal distance between upper and lower
knees is now greatly reduced. In other words, Fru2,6-BP lowers
the threshold for activation of PFK1 by Fru1,6-BP. Consequently,
Fru6-P does not have to build up as much to trigger a surge of
Fru1,6-BP, which both shortens the time to the next pulse and
reduces the size of the oscillation orbit, which encloses the two
knees (Fig. 4B, green dashed curve). Thus, the result is a smaller
orbit, a smaller oscillation amplitude, and a faster oscillation. If the
concentration of Fru2,6-BP is increased further, to 0.2 mM, the
lower knee moves to the left of the upper knee, so that the Fru1,6-
BP nullcline is no longer S-shaped (Fig. 4B, red). When this occurs,
the equilibrium becomes stable and the oscillatory solution
disappears (Fig. 4A, red). In this case, there is no threshold and
Fru-6P is continually converted to Fru1,6-BP. The high rate of
activity of PFK1 draws off Fru-6P as fast as it is produced, so that
there is constant production of Fru1,6-BP rather than cycles of
Fru6-P depletion followed by recovery of Fru6-P and a surge of
Fru1,6-BP production.
In summary, Fru2,6-BP speeds up and eventually terminates
glycolytic oscillations by taking the curvature out of the Fru1,6-BP
nullcline. Fru2,6-BP stimulates PFK1, making the PFK1-mediated
oscillation faster. However, if PFK1 is stimulated too much an
oscillation cannot be sustained, and instead the system comes to
rest with an elevated level of Fru1,6-BP.
We next use the Dual Oscillator Model (DOM) [8,38] of the
pancreatic b-cell to predict the effect of Fru2,6-BP on islets, which
utilize the muscle type (M-type) of PFK1 as well as other isoforms
[42]. This model consists of an electrical oscillator coupled to the
slower glycolytic oscillator illustrated in Fig. 4 and can produce a
range of behaviors, including compound bursting (fast Ca
2+
oscillations superimposed on slow oscillations) and slow bursting
(Ca
2+ oscillations with period of 3–7 min). We examine the effect
of Fru2,6-BP on slow bursting by incorporating Fru2,6-BP into the
PFK1 reaction function, as was done above for the stand-alone
glycolytic oscillator model. Unlike above, the Fru2,6-BP level is
determined by the PFK2 and FBPase2 reactions. That is,
dFru2,6{BP
dt
~JPFK2{JFBPase2 ð5Þ
where the reaction terms are given in Methods. In the model, we
consider three cases: (1) absence of the PFK2/FBPase2 molecule,
so that Fru2,6-BP=0, (2) PFK2/FBPase2 is present and the ratio
of the maximum reaction velocities VPFK2=VFBPase2 is 0.5, and (3)
the latter velocity ratio is increased to 2, increasing the Fru2,6-BP
concentration.
In the absence of PFK2/FBPase2, the DOM produces slow
mitochondrial NADH (NADHm) oscillations driven by glycolytic
oscillations, with a period of approximately 5 min (Fig. 5A). These
metabolic oscillations are reflected in oscillations in cytosolic Ca
2+
(Fig. 5B). When PFK2/FBPase2 is present at low to moderate
amounts, the metabolic oscillations become smaller and faster,
Figure 4. Fru1,6-BP oscillations produced by the two-variable
glycolytic oscillator model are modified by Fru2,6-BP. (A)
Addition of Fru2,6-BP can terminate the oscillations (red), or at an
intermediate level (green), make the oscillations faster and smaller. (B)
The Fru6-P nullcline (black) is unaffected by Fru2,6-BP, but Fru2,6-BP
pulls together the knees of the Fru1,6-BP nullcline (shown as solid blue,
then green and then red lines as Fru2,6-BP is increased as in (A)),
eventually stabilizing the equilibrium that exists at the intersection of
the Fru6-P and Fru1,6-BP nullclines. The orbit of the oscillation with
Fru2,6-BP=0 is shown (blue dashed line) along with an arrow indicating
the orientation of the orbit.
doi:10.1371/journal.pone.0034036.g004
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2+ oscillations. However,
when VPFK2=VFBPase2 is increased from 0.5 to 2.0, such that more
Fru2,6-BP is produced, the metabolic oscillations are terminated
(Fig. 5A). This leaves the electrical oscillator intact, so that fast
bursting and concomitant fast [Ca
2+]i oscillations are observed
(Fig. 5B). A similar series of behaviors can be produced by the
DOM in its compound bursting mode, although in this case there
is a smaller reduction in [Ca
2+] amplitude when VPFK2=VFBPase2.
Discussion
We have studied the bifunctional enzyme PFK2/FBPase2 in
pancreatic islets in order to determine its possible effects on
oscillatory activity. PFK2/FBPase2 was manipulated in two
different ways: (1) by overexpression of the kinase or phosphatase
moieties individually, and (2) by introducing point mutants to
selectively eliminate the kinase or phosphatase activities. Since the
point mutants are GK-interacting [21,23] but the truncation
mutants are not (Fig. S1), we were able to differentiate the effects
of PFK2/FBPase2 acting through Fru2,6-BP from those affecting
GK, both which bear on PFK1. The results of the PFK2 and
FBPase2 overexpression experiments in Fig. 2 were in good
qualitative agreement with the predictions of the Dual Oscillator
Model, namely, that enhancing the kinase function made slow
oscillations in [Ca
2+]i, a surrogate for metabolic oscillations
[11,37], faster and smaller in amplitude, whereas enhancing the
phosphatase function made them slower and larger. The point
mutants (Fig. 3) were also consistent with the predictions for
oscillation period, but no consistent effect on amplitude was
observed. By comparison, it has been shown experimentally that
the addition of Fru2,6-BP to rat skeletal muscle extracts exhibiting
glycolytic oscillations resulted in the termination of the oscillations
if given at a sufficiently high concentration [43]. Those oscillations
which were not terminated outright became faster and smaller as
Fru2,6-BP was increased. As we measured [Ca
2+]i, we could not
determine whether glycolytic oscillations were terminated, but
based on the increased frequency seen in islets in which PFK2 was
over-expressed, we suspect that this occurred in some cases. Thus,
the situation in muscle cells parallels our findings in islets.
Implications for computational models of the beta-cell
In muscle extracts, glycolytic oscillations are produced by the
autocatalytic feedback of Fru1,6-BP onto PFK1 [44–46]. The
mechanism of these oscillations, which has been well-defined in
yeast [44], is activation of PFK1 by its product and the subsequent
depletion of its substrate [41,42,45,46]. The period of these
oscillations (5–10 min) in muscle resembles the period of slow
insulin oscillations [7]. We observed good agreement between the
Dual Oscillator Model, which invokes this same mechanism to
generate glycolytic oscillations, and the data obtained from time-
lapse imaging of islet Ca
2+ oscillations under conditions of altered
PFK2/FBPase2 activity.
The evidence for the PFK1 hypothesis, first proposed by Corkey
and Tornheim and colleagues in 1988 (reviewed in [7]) is largely
indirect. Thus, the data we report here lend new support to the
Dual Oscillator Model. Although we cannot definitively rule out
alternative models in which metabolic oscillations occur down-
stream of glycolysis, such as in the mitochondria [47], or
secondary to Ca
2+ oscillations [48], the specific concordance
between the predictions and the measurements is difficult to
explain with these other models. For example, if the effect of
enhancing PFK2 activity were simply to increase glycolytic flux to
the mitochondria, we would not expect an increase in frequency
and a reduction in amplitude. Rather, the effect of PFK2 in the
experiments was consistent with its role in the model for its
product Fru2,6-BP to modulate the threshold for oscillations
driven by PFK1.
Feedback of PFK2/FBPase2 on glycolysis
We confirmed by FRET and immunoprecipitation that full-
length PFK2/FBPase2 interacts with GK, albeit weakly (Fig-
ure S1). Indeed, both islet and liver isoforms of PFK2/FBPase2
are reported to increase the Vmax of GK in cell lines [21,22],
which has been proposed to keep substrate available as Fru2,6-BP
lowers the PFK1 threshold and increases its activity. However, this
interaction is trumped by a much stronger effect of the
bifunctional enzyme on PFK1. That is, GK-interacting point
mutants had opposite effects on the oscillation period whereas they
would have the same effect on GK. A dominant effect of Fru2,6-
BP in islets is therefore concordant with the case in hepatocytes
[23] since in these cells the same kinase-dead and phosphatase-
dead mutants have strongly opposing affects on both Fru2,6-BP
levels and glycolytic flux.
We speculate that PFK2/FBPase2 is most helpful to the
glucose-sensing capacity of GK in a fasted organism, or in the
transition to threshold as glucose is elevated during feeding. In this
regard, the liver isoform of PFK2/FBPase2 exhibits a switch-like
behavior, with inactivation of the kinase and activation of the
bisphosphatase via phosphorylation at Ser-32 in the fasted state
[49], which is acutely reversed on refeeding, activating glycolysis
both by increasing Fru2,6-BP production and by enhancing
glucose phosphorylation [19]. This regulatory site is absent in the
beta-cell isoform, which is instead regulated by inactivation of the
bisphosphatase at Ser-466 by AMP-activated protein kinase
(AMPK) in the low energy state [23]. Nonetheless, PFK2/FBPase2
activity may lower the threshold for beta-cell oscillations – indeed
it can left-shift the dose-response curve for insulin release [20] –
whereas the oscillatory regime studied in our experiments
represents a fed state for the organism, when AMPK activity is
low. We leave this possibility for future work.
Figure 5. Simulations with the full Dual Oscillator Model. (A)
Mitochondrial NADH oscillations occur due to oscillations in glycolysis.
These are terminated when the ratio VPFK2/VPFK2, and thus the Fru2,6-BP
level, is sufficiently large. (B) Slow Ca
2+ oscillations are made faster and
smaller by the addition of PFK2/FBPase2, with VPFK2/VPFK2=0.5. They are
replaced by fast Ca
2+ oscillations when VPFK2/VPFK2=2.
doi:10.1371/journal.pone.0034036.g005
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main assumptions of the DOM and that PFK2/FBPase2 exerts its
effects on metabolic oscillations in beta-cells primarily through the
effect of its product Fru2,6-BP on PFK1 rather than through an
interaction with GK. It is of interest that whereas the product of
PFK2/FBPase2, Fru2,6-BP, affects PFK1 much more strongly
than Fru1,6-BP, the product of PFK1, Fru2,6-BP plays second
fiddle to Fru1,6-BP. This is because Fru1,6-BP endows PFK1 with
threshold properties via auto-catalysis while Fru2,6-BP is not auto-
catalytic for PFK1 and only modifies the threshold.
Materials and Methods
Culture and adenoviral infection of mouse pancreatic
islets
Experiments were carried out using male Swiss-Webster mice
(25–30 g) from Charles River Laboratories (Wilmington, MA).
Mice were sacrificed by cervical dislocation according to the
regulations of the University of Michigan Committee on the Use
and Care of Animals (UCUCA), who approved this study under
protocol number 10147. Islets were isolated from the pancreas as
in [50], and cultured overnight in RPMI1640 supplemented with
10% (v/v) fetal bovine serum (FBS), 100 units/ml penicillin and
100 mg/ml streptomycin (Invitrogen). Groups of 25 freshly-
isolated islets were immediately infected with 2000 MOI of each
adenoviral construct for 1.5 h in a 95/5% air/CO2 incubator at
37uC, followed by removal to fresh culture media lacking virus,
but containing either 1 mM Shield1 or vehicle (0.1% DMSO). To
estimate infection efficiency, Cherry-labeled cells were compared
with islet nuclei stained with Quant-iT PicoGreen (Invitrogen) for
1 h at 37uC and imaged live on a Nikon Instruments A1 Confocal
Microscope (Melville, NY).
Chemicals and expression constructs for live cell imaging
Mouse anti-human FKBP12 monoclonal antibodies, used at
1:500, were from BD Transduction Labs (cat. 610808), and
donkey anti-mouse HRP, used at 1:5000, was from Jackson Labs
(cat. 715-035-150). hield1 was purchased from Cheminpharma
(New Haven, CT). The cDNAS for mouse islet/brain PFK2/
FBPase2 (in pCMV-Sport6) and human beta-cell GK (in pOT-B7)
were obtained from Invitrogen (Carlsbad, CA), and subcloned into
a modified entry vector (pENTR1A-DS, Invitrogen) lacking the
CmR and ccdB cassettes (pEN), using the In-Fusion Advantage
PCR Cloning Kit (Clontech, Mountain View, CA). LR ClonaseII
was then used to transfer PFKFB2 and GK upstream or
downstream of monomeric cerulean or citrine contained in
custom built destination vectors modified from pcDNA6.2-V5/
DEST (Gateway System, Invitrogen). The resulting expression
vectors (pG-CMV-Cerulean-GK, pG-CMV-GK-Cerulean, pG-
CMV-Citrine-PFKFB2, pG-CMV-Cerulean-PFKFB2, pG-CMV-
PFKFB2-Citrine, and pG-CMV-PFKFB2-Cerulean), were then
used for FRET analysis as donor/acceptor pairs. To facilitate
inducible expression of PFKFB2 mutants, the pPTunerN-IRES2-
AcGFP vector (ProteoTuner System, Clontech) was purchased
from Clontech, and AcGFP was replaced with Cherry from
pLoxP-Cherry [51]. The entire expression cassette was then
transferred to pEN using the In-Fusion reaction, yielding pEN-
PTunerN-IRES2-Cherry. The 12 kDa TunerN cassette, which is
referred to above as the degradation domain (DD), is a mutant
FKBP12 which facilitates the rapid proteosomal degradation of
translated DD-tagged proteins; application of a cell-permeant
compound, Shield1, which binds the DD but not wildtype
FKBP12, protects DD-tagged fusion proteins from degradation
[25]. Again using the In-Fusion System, four mutants of PFKFB2
were cloned into the multiple cloning site downstream of the N-
terminal DD tag and a 17 aa linker sequence: the truncation
mutants PFKFB2
12250 (PFK2) and PFKFB2
2512518 (FBPase2);
and the kinase-dead H259A and phosphatase-dead T55V point
mutants, which were generated from full length PFKFB2
[26,31,33,51]. The resulting expression cassettes (DD-PFK2-
IRES2-Cherry, DD-FBPase2-IRES2-Cherry, DD-PFKFB2
H259A-
IRES2-Cherry, DD-PFKFB2
T55V-IRES2-Cherry), contained in
the pEN entry vector backbone, were subsequently transferred to
pAd/CMV/V5-DEST (Invitrogen) using Gateway Cloning.
Purified viruses were produced in HEK293T cells by the
University of Michigan Viral Vector Core. The sequence fidelity
of all constructs was verified by the University of Michigan DNA
Sequencing Core.
Timelapse imaging of islet Ca
2+ oscillations using Fura-2
Filter sets were used as previously described [50]. Islets were
placed in a glass bottom chamber (54 ml volume) (Warner
Instruments, Hamden, CT) on an Olympus IX-71 inverted
microscope equipped with a 0.3 N.A. UPlanFL/UIS2 10X
objective (Olympus). The recording solution (in mM: 137 NaCl,
5 KCl, 1.2 MgCl2, 2.6 CaCl2, 10 HEPES, 11.1 glucose; pH 7.4,
310 mOsm) was maintained at 33uC using inline and chamber
heaters, and perfused at a flow rate of 0.3 ml/min, first with
recording solution containing 1 mM Fura-2/AM in 0.1% DMSO
(Invitrogen, Carlsbad, CA) for 12 min, followed by an equivalent
washing period before monitoring [Ca
2+]i for 30 min. Fura-2
fluorescence was elicited by alternating excitation wavelengths of
340 and 380 nm at 0.2 Hz under the control of MetaFluor
software (Molecular Devices, Sunnyvale, CA). Changes in
intracellular Ca
2+ were expressed as 340/380 ratio. Offline
calculation of the average oscillatory periods and Ca
2+ amplitudes
were performed on the Ca
2+ traces after linear detrending using
custom macros written in Matlab (MathWorks, Natick, MA):
average period was determined as the dominant peak after Fast
Fourier Transform; the average amplitude was produced using a
peak-finding algorithm to detect the baseline and peak of each
oscillation, which were averaged for .20 min recording and
measured as DRatio (peak over baseline).
Co-immunoprecipitation
LR Clonase II was used to transfer PFKFB2 and GK into
pcDNA6.2-V5/DEST (Gateway System, Invitrogen). For each
treatment, a 6-well plate of confluent HEK293T cells (obtained
from the University of Michigan Vector Core) was transiently
transfected with the indicated constructs. After a 2-day expression
period, cells were rinsed twice in PBS and lysed in a Dounce
homogenizer in buffer containing 2% sucrose, 1 mM EDTA, and
20 mM Tris (pH 7.5). After the homogenate was centrifuged
(300 g for 3 min) to pellet the nuclei, the supernatant was diluted
1:1 in immunoprecipitation buffer (150 mM Tris, pH 7.4, 1 mM
MgCl2, 0.1 mM EGTA, 2% Triton X-100). Samples were
normalized for lysate volume and concentration (2–3 mg/ml) and
then incubated with 10 mg of anti-V5 monoclonal antibody
(Invitrogen) for 4 h at 4uC. The samples were then incubated
with Protein G-Sepharose beads (Pierce, Rockford, IL) for 1 h,
and washed in immunoprecipitation buffer. Finally the pellet was
resuspended in SDS sample buffer and fractionated by SDS-
PAGE and Western blotting. Polyclonal antibodies against PFK2
(::500) and GK (1:1000) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
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Stoichiometric FRET was performed on living Min6 cells plated
on glass-bottom dishes 18 hours after transfection with Lipfecta-
mine2000 (Invitrogen). Measurements were made on the heated
stage (33uC) of an Olympus IX-71 inverted fluorescence
microscope equipped with a 1.4 NA UPlanSApo 100X oil
immersion objective (Olympus America, Center Valley, PA), a
TILL Photonics Polychrome V xenon-lamp based monochrom-
eter (TILL-Photonics, Grafelfing, Germany), and a Photometrics
QuantEM 512sc camera (Tucson, AZ). Excitation light at 436 nm
(for the donor, Cerulean) and 500 nm (for the acceptor, Citrine)
was passed through a dual pass excitation filter (430/24; 500/20),
polychroic mirror (89006bs, Chroma Technology Corp., Brat-
tleboro, VT), and fluorescence emission was passed through a
DualView2 beamsplitter (Photometrics) containing a dichroic
mirror (T495lpxr) and emission filters (ET470/24m and ET535/
30) (Chroma) to allow simultaneous two channel monitoring of
donor and acceptor emission. All analyses of the acquired images
were performed using Metamorph (Molecular Devices). The
apparent efficiency of acceptor (Citrine) in complex (EA), the
apparent efficiency of donor (Cerulean) in complex (ED) and the
mole fraction of acceptor to donor (RATIO) values were
determined as described in [52], with modifications of [53]. The
characteristic efficiency of the linked cerulean-citrine construct was
measured by fluorescence lifetime to be 0.3014 [52]. Constants (a,
b, c, j) were empirically determined in Min6 cells (n.10 cells) for
each experiment, as described previously [52]. Apparent FRET
efficiency is reported as EAVG~
EAzED
2
.
The Dual Oscillator Model
The Dual Oscillator Model was developed to account for the
diverse oscillatory properties of pancreatic islets [8,38]. It consists
of three interacting components representing glycolysis, mito-
chondrial metabolism, and plasma membrane electrical activity
and Ca
2+ handling. Slow metabolic oscillations in the model are
produced by the glycolytic component, due to positive feedback
onto PFK1 by its product, Fru1,6-BP. This increases PFK1
activity until the substrate level (Fru6-P) falls below the level
needed to support PFK1 activity. The enzyme activity remains low
until the substrate level recovers, initiating the next oscillation
[41]. The glycolytic oscillations result in ATP/ADP oscillations,
which in turn affect the conductance of ATP-sensitive K
+ channels
in the plasma membrane. In this way, intrinsic metabolic
oscillations directly influence the electrical activity of the cell, as
well as Ca
2+ entry into the cell. The utilization of ATP to power
Ca
2+-ATPases in the plasma membrane and the endoplasmic
reticulum results in turn in a lowering of cytosolic ATP. Since ATP
is also an inhibitor of PFK1, this provides a pathway through
which the cell’s electrical activity indirectly affects the glycolytic
oscillator. Thus, the two oscillators, metabolic and electrical, are
bidirectionally coupled.
The Glycolytic Component
The glycolytic component of the model was developed by
Smolen [41], and all terms used in the model are described there,
as well as in Bertram et al. [37]. We add to this a differential
equation for the concentration of Fru2,6-BP and its stimulatory
effect on PFK1. In the modified model, the concentration of
Fru2,6-BP changes over time according to Eq. (5) in the Results.
The PFK2 reaction term is
JPFK2~VPFK2
Fru6{P
KPFK2zFru6{P

ð1Þ
and the FBPase2 reaction term is
JFBPase2~VFBPase2
Fru2,6{BP
KFBPase2zFru2,6{BP

ð2Þ
where KPFK2~50 mM and KFBPase2~0:1 mM [54]. The
maximum reaction rates (VPFK2,V FBPase2) are set to 0 in the
absence of PFK2/FBPase2. When PFK2/FBPase2 is present, we
set VPFK2~10{5 mMm s 21 and then use VFPBase2~2|10{5 or
VFPBase2~5|10{6 mMm s 21 to simulate the low and high ratios
of PFK2/FBPase2 in Fig. 5, respectively.
Fru1,6-BP enters the PFK1 reaction term, JPFK1, as an allosteric
stimulator with dissociation constant KFru1,6-BP. Fru2,6-BP com-
petes with Fru1,6-BP for binding to PFK1, so we replace
Fru1,6{BP
KFru1,6{BP
with
Fru1,6{BP
KFru1,6{BP
z
Fru1,6{BP
KFru2,6{BP
in the expression
for JPFK1. The values of the dissociation constants are from Foe et
al. [14]: KFru1,6-BP=1.0 mM and KFru2,6-BP=0.15 mM.
When the glycolytic component of the DOM is run in stand-
alone mode the concentration of ATP, which is inhibitory to
PFK1, is a fixed parameter. In the full DOM, however, the ATP
concentration varies dynamically due to mitochondrial ATP
production and cytosolic ATP utilization. As a result, the stand-
alone glycolytic oscillations are slower than those in the full DOM,
and we increase their frequency through the parameter m1~2 (see
Eqs. (3),(4)). This parameter is not included in the DOM.
Computer codes for the stand-alone glycolytic model and the
DOM are available as freeware at www.math.fsu.edu/ ˜bertram/
software/islet.
Supporting Information
Figure S1 Full-length PFK2/FBPase2 is required for interaction
with GK. (A) Co-immunoprecipitation of expressed PFK2/
FBPase2 from HEK293 lysates containing coexpressed V5-tagged
glucokinase (GK-V5). Anti-V5 was used for pulldown, and
polyclonal antibodies against glucokinase and PFK2 were used
in the Western Blots. No pulldown of PFK2/FBPase2 was
observed when GK-V5 was absent (top). Importantly, no co-
precipitation of GK was observed when FBPase2-V5 was
immunoprecipitated (IP; bottom). Cell lysates (L) and supernatants
(S) are shown for reference; FBPase2-V5 is present in the lysate,
but the band is feint at the level of image scaling required for the
IP band. (B) FRET measured by sensitized emission in living Min6
beta-cells transfected with PFK2/FBPase2-Cerulean and unlinked
Citrine (top) or Citrine-GK (bottom). The pseudocolored EAVG and
RATIO images represent a spatial map of FRET efficiency and
[Citrine]/[Cerulean], respectively; the color bar indicates scaling.
Our optical system was calibrated before each experiment using
cells expressing a linked Cerulean-Citrine construct, which was
independently measured by fluorescence lifetime as having a
characteristic efficiency (EC) of 0.30 [52], and which exhibited a
measured EAVG of 30.960.2% (n=35). (C) Averaged EAVG values
for each co-transfection condition. Note that only full-length
PFK2/FBPase2 interacts with GK (left). Furthermore, the results
indicate that fluoroprotein-labeled PFK2/FBPase2 forms dimers,
mediated by the interface of two opposing N-terminal PFK2
domains, while the FBPase2 domains are essentially independent
(right). These results are expected based on previous studies of liver
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obtained when the fluoroprotein tags were moved to the opposing
termini (not shown). The numbers in parentheses indicate the
number of cells imaged. Significant differences were determined
by ANOVA with a Bonferroni post-test (black bars, comparison is
to PFK2/FBPase2-Cerulean plus unlinked Citrine co-transfection
control), or ANOVA without a post-test (gray bars); ****,
p,0.0001.
(TIF)
Movie S1 3D reconstruction of a mouse pancreatic islet
transduced with adenovirus. Confocal imaging shows the
infection efficiency and penetration depth of adenovirus used to
deliver PFK2/FBPase2 mutants, based on expression of an
IRES2-linked Cherry (red). The islet was counterstained for 1 h
at 37uC with the cell-permeant dsDNA binding dye PicoGreen
(green), which labeled nuclei and some mitochondria, and imaged
live.
(AVI)
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